Your session is about to expire
← Back to Search
Targeted Therapy + Immunotherapy for Advanced Cancer
Study Summary
This trial is designed to study the safety and efficacy of targeted therapies or immunotherapy for people with unresectable, locally advanced or metastatic solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had cancer treatment in the last 2 weeks or 5 half-lives before starting this study.I am a man willing to use contraception or remain abstinent as required.My cancer has worsened after treatment or I haven't been treated because there are no suitable options.I had a precise radiation treatment within the last week.My blood and organs are functioning well.I am active and can care for myself regardless of my age.I am still recovering from a surgery that might affect the study's treatment.I do not have serious heart conditions or recent heart attacks.I am active and can care for myself regardless of my age.My cancer is advanced, cannot be surgically removed, and has spread.I haven't had another active cancer in the last 5 years that could affect this study.I have recovered from my last cancer treatment.I have not had whole brain radiotherapy in the last 14 days.
- Group 1: Cohort A: ROS1 Fusion-positive tumors (excluding NSCLC)
- Group 2: Cohort B: NTRK1/2/3 fusion-positive tumors
- Group 3: Cohort C: ALK fusion-positive tumors (excluding NSCLC)
- Group 4: Cohort D: TMB-high tumors
- Group 5: Cohort E: AKT1/2/3 mutant-positive tumors
- Group 6: Cohort G: MDM2-amplified, TP53 wild-type tumors
- Group 7: Cohort H: PIK3CA multiple mutant-positive tumors
- Group 8: Cohort K: RET fusion-positive tumors (excluding NSCLC)
- Group 9: Cohort L: KRAS G12C-positive tumors (excluding NSCLC and CRC)
- Group 10: Cohort M: ATM Loss of Function tumors
- Group 11: Cohort N: SETD2 Loss of Function tumors
- Group 12: Cohort J: BRAF class III mutant-positive tumors
- Group 13: Cohort F: HER2 mutant-positive tumors
- Group 14: Cohort I: BRAF class II mutant or fusion-positive tumors
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many different areas is this research being conducted?
"Patients are currently being accepted at the Ocala Oncology Center in Florida, The Icahn School of Medicine at Mount Sinai in New york, and The Hospital for Sick Children based in Toronto. In addition to these 50 sites, there are other recruitment locations."
What other Ipatasertib studies have been completed and what were the results?
"Ipatasertib was first studied in 2008 by Can Care Assoc Med Group Inc; Beach Cities Offices. So far, there have been 149 completed trials, with 428 live studies currently underway - many of which are being conducted out of Ocala, Florida."
Are we still looking for volunteers for this experiment?
"From what is available on clinicaltrials.gov, this study appears to be actively recruiting patients at the moment. The listing for this trial was first published on 18th January 2021 with the latest update being from 26th October 2022."
What are the medical conditions that Ipatasertib is approved to target?
"Ipatasertib is most frequently used as an anticancer medication. However, it can also be employed to treat conditions like therapeutic procedure, disease, and breast cancer (triple negative breast cancer (tnbc))."
How many participants are in this clinical trial?
"In order to successfully run this experiment,770 patients that fit the bill need to enroll. These individuals can come from locations such as Ocala Oncology Center in Ocala, Florida and Icahn School of Medicine at Mount Sinai in New york, New York."
When might Ipatasertib be cleared for general use?
"Ipatasertib's safety is supported by some data, giving it a score of 2."
Is this research project the first of its kind?
"A total of 428 ongoing clinical trials worldwide are using Ipatasertib as an investigational drug. These studies originated from 2101 cities and 77 countries, with the first one taking place in 2008. That trial, which was sponsored by Hoffmann-La Roche, completed its Phase 2 stage and involved 720 patients. To date, 149 similar trials have been run."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger